BCR downstream pathways are subsequently impacted by HSP90 inhibition, as demonstrated in MCL, classical Hodgkin lymphoma (cHL), and ABC-DLBCL, where IkB degradation and reduction of NFkB signaling are observed [62,63,69]. Here, HSP90AA1 is linked to mantle cell lymphoma.